The final results of the interferon beta-1b 16-year long-term follow-up study

The final results of the interferon beta-1b 16-year long-term follow-up study

Bibliografske podrobnosti
Main Authors:	Ebers, G, Traboulsee, A, Langdon, D, Reder, A, Miltenburger, C, Wolf, C, Konieczny, A
Format:	Conference item
Izdano:	2006

Podobne knjige/članki

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
od: Ebers, G, et al.
Izdano: (2009)

The interferon beta-1b 16-year long-term follow-up study: Neutralizing antibodies and clinical outcomes
od: Reder, A, et al.
Izdano: (2008)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
od: Ebers, G, et al.
Izdano: (2005)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
od: Goodin, D, et al.
Izdano: (2012)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
od: Goodin, D, et al.
Izdano: (2012)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
od: Ebers, G, et al.
Izdano: (2004)

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
od: Goodin, D, et al.
Izdano: (2012)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
od: Reder, A, et al.
Izdano: (2010)

EDSS and MRI burden of disease predict cognitive status at 16 years: data from the long term follow-up study
od: Langdon, D, et al.
Izdano: (2007)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
od: Ebers, G, et al.
Izdano: (2010)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
od: Sibley, W, et al.
Izdano: (1994)

Treatment of multiple sclerosis with interferon beta-1b - Reply
od: Sibley, W, et al.
Izdano: (1997)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
od: Petkau, A, et al.
Izdano: (2004)

Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
od: Bernard Uitdehaag, et al.
Izdano: (2011-01-01)

Experiences with interferon-beta-1b treatment in MS after three year follow-up
od: T Járdánházy, et al.
Izdano: (2002-05-01)

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL
od: Duquette, P, et al.
Izdano: (1995)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
od: Megen C. Wittling, et al.
Izdano: (2021-01-01)

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
od: Rice, G, et al.
Izdano: (1999)

Randomized controlled trial of interferon-beta-1a in secondary progressive MS - Clinical results
od: King, J, et al.
Izdano: (2001)

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY
od: Ebers, G, et al.
Izdano: (2011)

Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up
od: Jean-Pierre Villeneuve, et al.
Izdano: (1996-01-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
od: Petkau, A, et al.
Izdano: (2004)

Long Term Follow-Up of Patients with Chronic Hepatitis C Treated with Alpha Interferon
od: Jane D Collier, et al.
Izdano: (2000-01-01)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
od: Shannon Kolind, et al.
Izdano: (2022-01-01)

Beta-interferons in multiple sclerosis
od: Aggarwal Sourabh, et al.
Izdano: (2010-01-01)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
od: Mark S. Freedman, et al.
Izdano: (2024-01-01)

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
od: Francis, G, et al.
Izdano: (2001)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
od: Morris Cindy A, et al.
Izdano: (2005-02-01)

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma
od: Emmanuel Bachy, et al.
Izdano: (2013-07-01)

Treatment of multiple sclerosis with interferon beta-1 b.
od: Abdul-Ahad, A, et al.
Izdano: (1997)

Thrombotic microangiopathy associated with use of interferon-beta
od: Robles A, et al.
Izdano: (2012-06-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis (vol 352, pg 1498, 1998)
od: Ebers, G, et al.
Izdano: (1999)

Interferon beta treatment of multiple sclerosis.
od: Markovitz, D
Izdano: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
od: Mohamed Rayen Ganouni, et al.
Izdano: (2023-10-01)

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
od: Goodin, D, et al.
Izdano: (2012)

Analysis of the competitive load in u16 handballers as a function of the final result
od: David Mancha Triguero, et al.
Izdano: (2018-10-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
od: C. Carbonelli, et al.
Izdano: (2015-12-01)

Systemic interferon alfa in multiple sclerosis.
od: Weinshenker, BG, et al.
Izdano: (1989)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
od: Sørensen, P, et al.
Izdano: (2010)

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a
od: N. A. Spirina, et al.
Izdano: (2018-02-01)